At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
GP combine with Tislelizumab neoadjuvant therapy+CCRTdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of of GP Chemotherapy Combined With Tislelizumab Neoadjuvant Therapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: a Single-arm, Phase 2 Trial
In Brief
A Phase 2 clinical trial evaluating GP combine with Tislelizumab neoadjuvant therapy+CCRT for Nasopharyngeal Carcinoma. Completed, enrolled 63 participants across 1 site.
Detailed Summary
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy of locoregionally advanced nasopharyngeal carcinoma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartApr 2021
Primary CompletionMay 2025
TodayJul 2026
First PostedApr 6, 2021
Enrollment StartApr 14, 2021
Primary CompletionMay 30, 2025
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 5.2 years ago
Interventions
GP combine with Tislelizumab neoadjuvant therapy+CCRTdrug
chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy